Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
Ueda S, Saeki T, Shigekawa T, Omata J, Moriya T, Yamamoto J, Osaki A, Fujiuchi N, Misumi M, Takeuchi H, Sakurai T, Tsuda H, Tamura K, Ishida J, Abe Y, Imabayashi E, Kuji I, Matsuda H. Ueda S, et al. Among authors: yamamoto j. Int J Clin Oncol. 2012 Jun;17(3):276-82. doi: 10.1007/s10147-011-0287-2. Epub 2011 Aug 10. Int J Clin Oncol. 2012. PMID: 21830087
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J. Ueda S, et al. Among authors: yamamoto j. Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9. Breast Cancer. 2011. PMID: 20617404 Clinical Trial.
Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer.
Yamagishi Y, Yamasaki T, Ishida J, Moriya T, Einama T, Koiwai T, Fukumura-Koga M, Kono T, Hayashi K, Ueno H, Yamamoto J, Tsuda H. Yamagishi Y, et al. Among authors: yamamoto j. Ann Surg Oncol. 2020 Aug;27(8):2698-2710. doi: 10.1245/s10434-020-08269-0. Epub 2020 Mar 2. Ann Surg Oncol. 2020. PMID: 32124121 Free PMC article.
Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer.
Ueda S, Tsuda H, Saeki T, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Omata J, Moriya T, Fukatsu K, Yamamoto J. Ueda S, et al. Among authors: yamamoto j. Breast J. 2010 Nov-Dec;16(6):660-2. doi: 10.1111/j.1524-4741.2010.01011.x. Breast J. 2010. PMID: 21070448 No abstract available.
Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer.
Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, Kobayashi T, Yamamoto J, Tamura K, Ishida J, Abe Y, Yamamoto M, Mochizuki H. Ueda S, et al. Among authors: yamamoto j, yamamoto m, yamamoto s. BMC Cancer. 2008 Dec 22;8:384. doi: 10.1186/1471-2407-8-384. BMC Cancer. 2008. PMID: 19102762 Free PMC article.
Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with long-term follow-up.
Takeshita T, Tsuda H, Moriya T, Yamasaki T, Asakawa H, Ueda S, Sato K, Aida S, Tamai S, Matsubara O, Hase K, Yamamoto J. Takeshita T, et al. Among authors: yamamoto j. Ann Surg Oncol. 2012 Apr;19(4):1160-6. doi: 10.1245/s10434-011-2085-5. Epub 2011 Oct 12. Ann Surg Oncol. 2012. PMID: 21989659
1,882 results